What is the official website of Novartis ?

The official website of Novartis is http://www.novartis.com.

What is Novartis's cybersecurity risk score?

Novartis has an AI-generated cybersecurity risk score of 810 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Novartis experienced?

According to Rankiteo, Novartis currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis is not certified under SOC 2 Type 1.

Does Novartis have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis does not hold a SOC 2 Type 2 certification.

Does Novartis comply with GDPR ?

According to Rankiteo, Novartis is not listed as GDPR compliant.

Does Novartis have PCI DSS certification ?

According to Rankiteo, Novartis does not currently maintain PCI DSS compliance.

Does Novartis comply with HIPAA ?

According to Rankiteo, Novartis is not compliant with HIPAA regulations.

Does Novartis have ISO 27001 certification ?

According to Rankiteo,Novartis is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis operate in ?

Novartis operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis have ?

Novartis employs approximately 86,785 people worldwide.

Does Novartis own any subsidiaries ?

Novartis presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis have ?

Novartis's official LinkedIn profile has approximately 4,751,735 followers.

What is the NAICS classification code for Novartis ?

Novartis is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis have a Crunchbase profile ?

No, Novartis does not have a profile on Crunchbase.

Does Novartis have a LinkedIn profile ?

Yes, Novartis maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis.

How many cybersecurity incidents has Novartis experienced ?

As of September 28, 2026, Rankiteo reports that Novartis has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis have ?

Novartis has an estimated 5,769 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis

Boost Score +25 with badge (5 left)

810

/1000

Good

835

/1000

Good

Novartis Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Novartis

Novartis CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Novartis has 30.56% fewer incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs All-Companies Average (This Year)

Novartis has 1.96% fewer incidents than the average of all companies with at least one recorded incident.

Incident Types Novartis vs Pharmaceutical Manufacturing Industry Avg (This Year)

Novartis reported 1 incidents this year: 0 cyber attacks, 0 ransomware, 0 vulnerabilities, 1 data breaches, compared to industry peers with at least 1 incident.

Incident History - Novartis (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Subsidiaries

Novartis

Pharmaceutical Manufacturing

Website: http://www.novartis.com

Company Size: 10,001+ employees

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis MalaysiaPharmaceutical Manufacturing

Loading…

Novartis Similar Companies

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Loading…

NEWS

Novartis CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

September 08, 2026 05:41 AM

Novartis Phase III HARBOR Study Misses Primary Endpoint in DM1

Novartis said on September 8, 2026 that the global Phase III HARBOR study evaluating delpacibart etedesiran (del-desiran) in people living...

Read Article

September 01, 2026 05:32 AM

Novartis Reports Positive Phase III RMS Results for Remibrutinib

Novartis on September 1, 2026 announced positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in...

Read Article

August 06, 2026 08:50 AM

How Novartis optimized its supply chain

A data-driven, globally integrated solution helps Novartis manage high inventory, slow- and non-moving goods and audit risks.

Read Article

August 03, 2026 07:00 AM

Amgen says patient health data, IP stolen in cybersecurity breach

Hackers recently accessed Amgen's cloud environment, stealing patient health information and proprietary company data,...

Read Article

July 06, 2026 07:00 AM

Recon: Novartis to acquire Myricx Bio for $1.1B; Republican lawmakers press FDA to ensure trials are diverse

I spoke to Anthropic's CEO about how AI may affect biotech. Here's what I learned (STAT); Medicare takes another swing at 340B cuts to...

Read Article

May 21, 2026 07:00 AM

BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus

Bristol Myers Squibb looks to Texas; Novartis looks to remove CDMO from its Slovenia campus; and more.

Read Article

May 20, 2026 07:00 AM

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Role models for students, parents, educators, and the cybersecurity community Sponsored by Secureworks.

Read Article

April 23, 2026 11:56 AM

The cyber risk operations center in the age of AI

The cyber risk operations center as the next-generation cybersecurity operating model, placing risk intelligence at the center of decision-making.

Read Article

March 25, 2026 07:00 AM

Novartis sued for allegedly leaking data on breast cancer patient to Google, Contentsquare

In a lawsuit seeking class action status, a woman identified as “P.M.” said she began using the website for Kisqali, a Novartis breast...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-100739

SUMMARY

A vulnerability was detected in mathurvishal CloudClassroom-PHP-Project up to 5dadec098bfbbf3300d60c3494db3fb95b66e7be. This impacts an unknown function of the file viewresult.php. Performing a manipulation of the argument seno results in sql injection. Remote exploitation of the attack is possible. The exploit is now public and may be used. This product follows a rolling release approach for continuous delivery, so version details for affected or updated releases are not provided. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-26

Updated

Date2026-09-26

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-94408

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Elasticsearch can lead denial of service via Excessive Allocation (CAPEC-130)

Published

Date2026-09-26

Updated

Date2026-09-26

RISK INFORMATION (Score: 4.9)

cvss3

Base Score: 4.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

1.2

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-22-9-4-7-9-5-3-security-update-esa-2026-184/390688

CVE-2026-94400

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead denial of service via Excessive Allocation (CAPEC-130)

Published

Date2026-09-26

Updated

Date2026-09-26

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-22-9-4-7-9-5-3-security-update-esa-2026-181/390685

CVE-2026-94399

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Elasticsearch can lead denial of service via Excessive Allocation (CAPEC-130)

Published

Date2026-09-26

Updated

Date2026-09-26

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-22-9-4-7-9-5-4-security-update-esa-2026-180/390684

CVE-2026-94398

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Elasticsearch can lead denial of service via Excessive Allocation (CAPEC-130)

Published

Date2026-09-26

Updated

Date2026-09-26

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-22-9-4-7-9-5-4-security-update-esa-2026-179/390683

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Vendor Cyber Rating & Cyber Score

Novartis A.I CyberSecurity Scoring

Novartis CyberSecurity News & History

Novartis Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis (X = Date, Y = Severity)

Novartis Subsidiaries

Novartis

Novartis Similar Companies

Servier

MANKIND PHARMA LTD

AbbVie

Bristol Myers Squibb

Merck Group

Parexel

Cipla

Teva Pharmaceuticals

Grifols

Novartis CyberSecurity News

Novartis Phase III HARBOR Study Misses Primary Endpoint in DM1

Novartis Reports Positive Phase III RMS Results for Remibrutinib

How Novartis optimized its supply chain

Amgen says patient health data, IP stolen in cybersecurity breach

Recon: Novartis to acquire Myricx Bio for $1.1B; Republican lawmakers press FDA to ensure trials are diverse

BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

The cyber risk operations center in the age of AI

Novartis sued for allegedly leaking data on breast cancer patient to Google, Contentsquare

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis CyberSecurity News & History

Novartis Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis (X = Date, Y = Severity)

Novartis Subsidiaries

Novartis

Novartis Similar Companies

Servier

MANKIND PHARMA LTD

AbbVie

Bristol Myers Squibb

Merck Group

Parexel

Cipla

Teva Pharmaceuticals

Grifols

Novartis CyberSecurity News

Novartis Phase III HARBOR Study Misses Primary Endpoint in DM1

Novartis Reports Positive Phase III RMS Results for Remibrutinib

How Novartis optimized its supply chain

Amgen says patient health data, IP stolen in cybersecurity breach

Recon: Novartis to acquire Myricx Bio for $1.1B; Republican lawmakers press FDA to ensure trials are diverse

BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

The cyber risk operations center in the age of AI

Novartis sued for allegedly leaking data on breast cancer patient to Google, Contentsquare

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo